Loading stock data…
ICCC
$8.73+0.27 (+3.19%)
Market ClosedLast close May 1
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ImmuCell Corporation in the Healthcare sector is trading at $8.73. The stock is currently near its 52-week high of $8.82, remaining 37.7% above its 200-day moving average. Technical signals show overbought RSI of 79 and bullish MACD crossover, explaining why ICCC maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 79) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$8.73
Potential Upside
5%
Whystock Fair Value$9.17
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastit...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$72.37M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.31
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-23.30%
Volume
Today's trading volume
17,974
Recent News
The Zacks Analyst Blog The Goldman Sachs, NextEra, Shopify, Landmark and ImmuCell
Goldman Sachs, NextEra Energy and Shopify lead top stock reports, highlighting strong gains, expanding operations and strategic shifts driving growth.
Top Stock Reports for Goldman Sachs, NextEra Energy & Shopify
Goldman Sachs, NextEra Energy and Shopify headline fresh analyst reports, spotlighting strong gains, expansion plans and key risks shaping outlooks.
ImmuCell Corp (ICCC) Q4 2025 Earnings Call Highlights: Navigating Growth Amidst Challenges
ImmuCell Corp (ICCC) reports improved profitability and gross margins, while addressing sales declines and strategic shifts for future growth.
ImmuCell 2025 Net Loss Narrows Y/Y as Sales & Margins Improve
ICCC's 2025 sales rise 4.3% y/y, with the gross margin expanding sharply, helping narrow its annual net loss despite asset write-downs and strategic shifts.
ImmuCell Q4 Earnings Call Highlights
ImmuCell (NASDAQ:ICCC) executives used the company’s fourth-quarter and full-year 2025 earnings call to highlight a year of operational change, improved margins, and a strategic pivot toward expanding its First Defense calf scours prevention franchise while stepping away from investment in its Re-Ta